InvestSMART

Cleo Diagnostics Ltd (ASX: COV) - Announcements

Current share price for COV : $0.300 0.005 (1.69%)+

ASX company news and announcements for Cleo Diagnostics Ltd (COV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cleo Diagnostics Ltd (COV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cleo Diagnostics Ltd (COV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cleo Diagnostics Ltd (COV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$41 Restricted securities to be released from escrow 27 Oct 2023 3:43PM $0.170 $0.300 risen by 76.47%
$41 Application for quotation of securities - COV 13 Oct 2023 4:25PM $0.170 $0.300 risen by 76.47%
$41 Cleo Delivers Early Progress on Development Program 9 Oct 2023 9:46AM $0.180 $0.300 risen by 66.67%
$41 Restricted securities to be released from escrow 6 Oct 2023 4:16PM $0.180 $0.300 risen by 66.67%
$41 Letter to Shareholders 5 Oct 2023 4:17PM $0.175 $0.300 risen by 71.43%
$41 Notice of Annual General Meeting/Proxy Form 5 Oct 2023 4:13PM $0.175 $0.300 risen by 71.43%
$41 Cleo Enhances Board Capacity 2 Oct 2023 9:15AM $0.180 $0.300 risen by 66.67%
$41 Appendix 4G and Corporate Governance Statement 27 Sep 2023 4:32PM $0.175 $0.300 risen by 71.43%
$41 Annual Report to shareholders 27 Sep 2023 4:20PM $0.175 $0.300 risen by 71.43%
$41 Notice Required Under ASX Listing Rule 3.13.1 22 Sep 2023 4:35PM $0.190 $0.300 risen by 57.89%
$41 Change of Registry Address 21 Sep 2023 4:10PM $0.200 $0.300 risen by 50%
$41 Application for quotation of securities - COV 19 Sep 2023 5:01PM $0.195 $0.300 risen by 53.85%
$41 Restricted securities to be released from escrow 12 Sep 2023 4:29PM $0.200 $0.300 risen by 50%
$41 Letter from the CEO to Shareholders 1 Sep 2023 9:20AM $0.200 $0.300 risen by 50%
$41 Appendix 4E and Preliminary Financial Report 31 Aug 2023 4:31PM $0.200 $0.300 risen by 50%
$41 CLEO Granted U.S. Patent for Novel Ovarian Cancer Biomarker 22 Aug 2023 9:09AM $0.225 $0.300 risen by 33.33%
$41 Initial Directors Interest Notices x 5 21 Aug 2023 7:01PM $0.225 $0.300 risen by 33.33%
$41 Notice of initial substantial holders x 3 21 Aug 2023 5:43PM $0.225 $0.300 risen by 33.33%
$41 Pre-Quotation Notice 18 Aug 2023 3:19PM $0.225 $0.300 risen by 33.33%
$41 Distribution Schedule 18 Aug 2023 3:18PM $0.225 $0.300 risen by 33.33%
$41 Top 20 Holders 18 Aug 2023 3:18PM $0.225 $0.300 risen by 33.33%
$41 Securities Trading Policy 18 Aug 2023 3:17PM $0.225 $0.300 risen by 33.33%
$41 Employee Securities Incentive Plan 18 Aug 2023 3:16PM $0.225 $0.300 risen by 33.33%
$41 Interim Report 31 December 2022 18 Aug 2023 2:38PM $0.225 $0.300 risen by 33.33%
$41 Annual Report 30 June 2022 18 Aug 2023 2:37PM $0.225 $0.300 risen by 33.33%

101 - 125 of 154 results

Page 5 of 7

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.